87 related articles for article (PubMed ID: 973988)
1. The ralationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine.
Orr MW; Boullin DJ
Br J Clin Pharmacol; 1976 Oct; 3(5):925-8. PubMed ID: 973988
[TBL] [Abstract][Full Text] [Related]
2. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine.
Boullin DJ; Woods HF; Grimes RP; Grahame-Smith DG
Br J Clin Pharmacol; 1975 Feb; 2(1):29-35. PubMed ID: 791316
[TBL] [Abstract][Full Text] [Related]
3. The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients.
Orr MW; Knox JM; Allen R; Gelder MG; Grahame-Smith DG
Br J Clin Pharmacol; 1981 Mar; 11(3):255-9. PubMed ID: 6111333
[TBL] [Abstract][Full Text] [Related]
4. Neuroleptic effects on platelet aggregation: a study in normal volunteers and schizophrenics.
Dinan TG
Psychol Med; 1987 Nov; 17(4):875-81. PubMed ID: 2893407
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites.
Boullin DJ; Grahame-Smith DG; Grimes RP; Woods HF
Br J Pharmacol; 1975 Jan; 53(1):121-5. PubMed ID: 1125484
[TBL] [Abstract][Full Text] [Related]
6. Increased platelet aggregation in patients receiving chlorpromazine: responses to 5-hydroxytryptamine, dopamine and N-dimethyl dopamine.
Boullin DJ; Grimes RP
Br J Clin Pharmacol; 1976 Aug; 3(4):649-53. PubMed ID: 22216508
[TBL] [Abstract][Full Text] [Related]
7. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
8. Serotonin receptor site in human platelets from control and chlorpromazine treated subjects.
Oppenheim B; Hefez A; Youdim MB
Prog Biochem Pharmacol; 1980; 16():119-32. PubMed ID: 7443729
[TBL] [Abstract][Full Text] [Related]
9. Comparative enzyme-inducing effects of chlorpromazine and fluphenazine therapies in psychotic patients.
Harman AW; Frewin DB; Priestly BG
Psychopharmacology (Berl); 1980; 69(1):35-7. PubMed ID: 6771823
[TBL] [Abstract][Full Text] [Related]
10. Resuspension of platelets: enhanced 5-hydroxytryptamine-induced aggregation in chlorpromazine treated patients due to changes in platelet properties.
Boullin DJ; Grahame-Smith DG; Grimes RP; Woods HF
Br J Clin Pharmacol; 1975 Feb; 2(1):37-9. PubMed ID: 791317
[TBL] [Abstract][Full Text] [Related]
11. Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.
Youdim MB; Hefez A; Oppenheim B
Br J Clin Pharmacol; 1981 Oct; 12(4):535-42. PubMed ID: 7295487
[TBL] [Abstract][Full Text] [Related]
12. Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine.
Boullin DJ; Glenton PA
Br J Pharmacol; 1978 Apr; 62(4):537-42. PubMed ID: 26445
[TBL] [Abstract][Full Text] [Related]
13. The reliability of 5-hydroxytryptamine induced platelet aggregation responses in schizophrenic patients treated with neuroleptic drugs.
Knox JM; Orr MW; Allen R; Gelder MG; Grahame-Smith DG
Br J Clin Pharmacol; 1981 Mar; 11(3):261-3. PubMed ID: 6111334
[TBL] [Abstract][Full Text] [Related]
14. Effects of aspirin and prostaglandin E2 on secondary phase aggregation responses of schizophrenic patients treated with chlorpromazine.
Boullin DJ; Orr MW
Br J Clin Pharmacol; 1976 Oct; 3(5):929-33. PubMed ID: 973989
[TBL] [Abstract][Full Text] [Related]
15. Antiparkinsonian agents and fluphenazine decanoate.
Idzorek S
Am J Psychiatry; 1976 Jan; 133(1):80-2. PubMed ID: 1247126
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate.
Kane J; Quitkin F; Rifkin A; Klein DF
Am J Psychiatry; 1978 Dec; 135(12):1539-42. PubMed ID: 717574
[TBL] [Abstract][Full Text] [Related]
17. Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.
Serebruany VL; El Mouelhi M; Pfannkuche HJ; Rose K; Marro M; Angiolillo DJ
Am J Ther; 2010; 17(6):543-52. PubMed ID: 19797939
[TBL] [Abstract][Full Text] [Related]
18. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
Cookson JC; Kennedy NM; Gribbon D
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
[TBL] [Abstract][Full Text] [Related]
19. Long-acting formulation leading to severe long-term adverse effects: a case report of fluphenazine and persistent extrapyramidal symptoms.
Omi T; Mitsui Y; Matsunaga H
J Clin Pharm Ther; 2018 Feb; 43(1):117-120. PubMed ID: 28718220
[TBL] [Abstract][Full Text] [Related]
20. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
